Cargando…

Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome

Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, in which control of serum uric acid (S-UA) levels is important. S-UA-lowering efficacy of a new xanthine oxidase inhibitor, febuxostat, was retrospectively evaluated in seven patients with hematological malignancies who were at...

Descripción completa

Detalles Bibliográficos
Autores principales:	TAKAI, MIHOKO, YAMAUCHI, TAKAHIRO, FUJITA, KEI, LEE, SHIN, OOKURA, MIYUKI, KISHI, SHINJI, URASAKI, YOSHIMASA, YOSHIDA, AKIRA, IWASAKI, HIROMICHI, UEDA, TAKANORI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156226/ https://www.ncbi.nlm.nih.gov/pubmed/25202361 http://dx.doi.org/10.3892/ol.2014.2394

Ejemplares similares

Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia
por: Ookura, Miyuki, et al.
Publicado: (2018)

Monitoring of Intracellular l‐βD‐Arabinofuranosylcytosine 5′‐Triphosphate in 1‐β‐D‐Arabinofuranosylcytosine Therapy at Low and Conventional Doses
por: Yamauchi, Takahiro, et al.
Publicado: (2001)

Close Correlation of 1‐β‐D‐Arabinofuranosylcytosine 5′‐Triphosphate, an Intracellular Active Metabolite, to the Therapeutic Efficacy of N(4)‐Behenoyl‐1‐β‐D‐arabinofuranosylcytosine Therapy for Acute Myelogenous Leukemia
por: Yamauchi, Takahiro, et al.
Publicado: (2001)

YM155 exerts potent cytotoxic activity against quiescent (G(0)/G(1)) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1
por: Ookura, Miyuki, et al.
Publicado: (2017)

Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis
por: YAMAUCHI, TAKAHIRO, et al.
Publicado: (2015)

Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
por: Maie, Koichiro, et al.
Publicado: (2014)

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat
por: Sheer, Richard, et al.
Publicado: (2017)

Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Successful Administration of Recombinant Human Soluble Thrombomodulin α (Recomodulin) for Disseminated Intravascular Coagulation during Induction Chemotherapy in an Elderly Patient with Acute Monoblastic Leukemia Involving the t(9;11)(p22;q23) MLL/AF9 Translocation
por: Takagi, Kazutaka, et al.
Publicado: (2011)

Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group
por: Sakai, Tomoyuki, et al.
Publicado: (2015)

Uric Acid and the Prediction Models of Tumor Lysis Syndrome in AML
por: Ejaz, A. Ahsan, et al.
Publicado: (2015)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
por: Wu, Le, et al.
Publicado: (2021)

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease
por: Peng, Yueh-Lung, et al.
Publicado: (2020)

Tetracyclines downregulate the production of LPS-induced cytokines and chemokines in THP-1 cells via ERK, p38, and nuclear factor-κB signaling pathways
por: Sun, Jian, et al.
Publicado: (2015)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
por: Zheng, Yanqun, et al.
Publicado: (2022)

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients
por: Sofue, Tadashi, et al.
Publicado: (2014)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Enhancement of Ca(2+)‐dependent Endonuclease Activity in L1210 Cells during Apoptosis Induced by 1‐β‐D‐Arabinofuranosylcytosine: Possible Involvement of Activating Factor(s)
por: Takauji, Rumiko, et al.
Publicado: (1995)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis
por: Araie, Hiroaki, et al.
Publicado: (2017)

Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome
por: Trachsler, Johannes, et al.
Publicado: (2008)

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
por: Suzuki, Satoshi, et al.
Publicado: (2021)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Febuxostat for the Prevention of Recurrent 2,8-dihydroxyadenine Nephropathy due to Adenine Phosphoribosyltransferase Deficiency Following Kidney Transplantation
por: Nanmoku, Koji, et al.
Publicado: (2017)

Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
por: Yan, Fei, et al.
Publicado: (2022)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
por: Kraev, Krasimir Iliev, et al.
Publicado: (2023)

Rasburicase-Induced Falsely Low Measurement of Uric Acid in Tumor Lysis Syndrome: A Report of Two Cases
por: Yu, Lian, et al.
Publicado: (2023)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0dafssneu2da4o8ae44lomileu